Global Deoxyribonucleic Acid (DNA) Vaccines Market is valued at USD 4.28 Billion in 2022 and is projected to attain a value of USD 7.41 Billion by 2030 at a CAGR of 7.10% during the forecast period, 2022–2028. Deoxyribonucleic Acid (DNA) Vaccines are made up of deoxyribonucleic acid (DNA), which encodes antigens and generates a broader variety of immune responses in the body with minimal adverse effects. The Deoxyribonucleic Acid (DNA) Vaccines approach involves delivering the gene to cells, which then expresses the gene and produces the desired protein. Clinical trials utilising Deoxyribonucleic Acid (DNA) Vaccines in the treatment of metastatic melanoma, prostate carcinoma, pancreatic cancer, and other solid tumours have showed promising outcomes. Due to factors such as the use of Deoxyribonucleic Acid (DNA) Vaccines in healthcare, low cost, growing technology, fewer side effects, increased knowledge of healthcare professionals, and others, demand for Deoxyribonucleic Acid (DNA) Vaccines is rapidly expanding.
Deoxyribonucleic Acid (DNA) Vaccines Market Size, 2022 To 2030 (USD Billion)
Factors such as the growing population, the need to expand healthcare access, the rising prevalence of chronic diseases and conditions, a physician shortage, advancements in telecommunications, government support, increasing awareness, and increasing technology adoption are all driving growth in the Deoxyribonucleic Acid (DNA) Vaccines Market.
Rising Demand for Effective Treatment of Infectious Disease is Driving Market Growth
Report Coverage & Deliverables
- Real-Time Data Updates:
- Competitor Benchmarking
- Market Trends Heatmap
- Custom Research Queries
- Market Sentiment Analysis
- Demographic and Geographic Insights
Increase in the number of cases of HIV, cancer, hepatitis, and other diseases, as well as an increase in government investment in Deoxyribonucleic Acid (DNA) Vaccines and an increase in the number of antibiotic-resistant pathogens have created the need for effective and low-cost vaccination, which are among the major factors driving the Deoxyribonucleic Acid (DNA) Vaccines Market. Deoxyribonucleic Acid (DNA) Vaccines are used to destroy and stop germs from growing. These medications can operate as a human body's defensive mechanism, neutralising the effects of disease-causing chemicals. There is a growing demand for infectious disease therapy because to increased research activities, increased awareness, and substantial R&D pharmaceuticals.
Limited Efficiency of Plasmid-Based Techniques
The immunological impact, tissue distribution and persistence after injection, and whether the Deoxyribonucleic Acid (DNA) Vaccines can escape into the environment are the primary areas of question. As a result, the expansion of Deoxyribonucleic Acid (DNA) Vaccines faces a significant challenge. One of the problems for the Deoxyribonucleic Acid (DNA) Vaccines Market is the limited efficiency of plasmid-based approaches, which prevents their usage in the construction of more accurate human cell models.
The Global Deoxyribonucleic Acid (DNA) Vaccines Market can be segmented by Application, into Human Diseases, Veterinary Diseases Allergies and Others. On the basis of Type, the Deoxyribonucleic Acid (DNA) Vaccines Market is segmented into Human DNA Vaccines and Animal DNA Vaccines. Based on Region, the Market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Below tree is interactive. You can click the nodes to get more information.
North America to Continue Dominating the Deoxyribonucleic Acid (DNA) Vaccines Market
North America is the market leader, followed by Europe. Owing to the rapid advancements in immunology and molecular biology, as well as an increase in the number of cases of HIV, cancer, hepatitis, and other diseases, as well as an increase in government investment in Deoxyribonucleic Acid (DNA) Vaccines and an increase in the number of antibiotic-resistant pathogens, North America dominates the market for deoxyribonucleic acid (DNA) vaccines.
Some of the players are Inovio Biomedical Corp, Merck & Co., Mitsubishi Tanabe, Dendreon Corporation, ASTELLAS PHARMA, Dynavax Technologies, Sanofi, Tekmira Pharmaceuticals GlaxoSmithKline Corp, Protein Sciences Corp.among others.
Deoxyribonucleic Acid (DNA) Vaccines Market is segmented as follows:
- Types (Human DNA Vaccines, Animal DNA Vaccines)
- Application (Human diseases, Veterinary Diseases , Allergies and Others)
- Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
|Regions & Countries Covered
- North America - (U.S., Canada, Mexico)
- Europe - (U.K., France, Germany, Italy, Spain, Rest Of Europe)
- Asia Pacific - (China, Japan, India, South Korea, South East Asia, Rest Of Asia Pacific)
- Latin America - (Brazil, Argentina, Rest Of Latin America)
- Middle East & Africa - (GCC Countries, South Africa, Rest Of Middle East & Africa)
- Inovio Biomedical Corp
- Merck & Co.
- Mitsubishi Tanabe
- Dendreon Corporation
- ASTELLAS PHARMA
- Dynavax Technologies
- Tekmira Pharmaceuticals GlaxoSmithKline Corp
- Protein Sciences Corp.among others
||Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST
analysis, value chain analysis, regulatory landscape, technology landscape, patent analysis, market
attractiveness analysis by segments and North America, company market share analysis, and COVID-19
Pricing and purchase options
||Avail of customized purchase options to meet your exact research needs. Explore purchase options
Deoxyribonucleic Acid (DNA) Vaccines Market is tabulated as follows: